Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO21--BMS Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival.....

Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Bristol-Myers Squibb was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene, which the drugmaker bought in 2019. According to a complaint in Manhattan federal court, Bristol-Myers failed to use contractually required “diligent efforts” to win US Food and Drug Administration approval for.

Bristol-Myers Squibb sued for $6.4B over delayed cancer drug

Bristol Myers Squibb Co (NYSE: BMY) was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, acquired in 2019 for $80.3 billion in cash and stock. According to a complaint in Manhattan federal court, Bristol Myers failed to use contractually required "diligent efforts" to win FDA approval for the non-Hodgkin lymphoma drug by December 31, 2020, deadline.

Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters

A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.

Lawsuit says Bristol-Myers avoided $6.4 billion payment by delaying cancer drug

The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Yervoy for the first-line treatment of malignant pleural mesothelioma.

Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Bernstein's 37th Annual Strategic Decisions Conference (Transcript)

The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM). The approvals are based on results from the CheckMate -743 trial.

Bristol Myers' Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Deucravacitinib--Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases

Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma

BMS stock has had a stagnant few years but there are real signs of momentum at the company. On May 21st, shares reached their highest trading price of $67.5 since early 2018.

Bristol-Myers Squibb: Investment Case Getting Better And Better - A Great Time To Buy

Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.

Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis

The FDA has approved Bristol Myers Squibb & Co's (NYSE: BMY) Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD). A European marketing application for Zeposia for moderately to severely active UC is currently under review, with a regulatory decision expected in the second half of 2021.

Bristol-Myers' Zeposia Scores FDA Approval For Ulcerative Colitis

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--U.S. FDA Approves Bristol Myers Squibb's Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1

American Tower

British American Tobacco

Enbridge

Johnson & Johnson

Altria

Philip Morris

Invesco QQQ

S&P Global

SPDR S&P 500 ETF Trust

AT&T

When someone gives you a choice: ask if you can have both? Inflation might be transitory, it might also be here to stay.

Become Inflation Proof: Buy These 4 High Quality Dividend Growth Stocks

AbbVie

General Motors

Merck

Sirius XM Holdings Inc

Warren Buffett is a legendary investor, but he's wrong to pare down these top-tier stocks.

5 Stocks Warren Buffett Is Selling That You Should Be Buying

Intel

They're safe companies that also regularly raise their payouts.

2 Top Dividend Stocks for a Better Retirement

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions Conference

Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions Conference

Bristol-Myers Squibb Company (BMY) Management Presents at 2021 UBS Global Healthcare Virtual Conference (Transcript)

Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access to Xencor's Xtend Fc technology to extend the half-life of a novel antibody combination therapy for COVID-19. Under the terms of the agreement, Bristol Myers Squibb will have sole responsibility for supporting and advancing the research, development, regulatory and commercial activities for SARS-CoV-2 mAb Duo.

Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies

Amgen

General Dynamics

Lockheed Martin

Pfizer

7 High-Quality Dividend Growth Stocks Trading Below Fair Value

Xencor

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it has entered into a technology license agreement with Bristol-Myers Squibb Company (NYSE:BMY) under which Bristol Myers Squibb will have non-exclusive access to Xencor's Xtend™ Fc technology to extend the half-life of a novel antibody combination therapy that is i

Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Host Virtual Investor Event to Discuss ASCO 2021 Highlights

Bristol Myers Squibb to Host Virtual Investor Event to Discuss ASCO 2021 Highlights

Bristol Myers' (BMY) Opdivo in combination with Yervoy gets positive CHMP recommendation by the EMA for an additional indication.

Bristol Myers' (BMY) Opdivo-Yervoy Combo Gets Positive CHMP Opinion

Bristol-Myers Squibb & Co (NYSE: BMY) released positive new data on its ulcerative colitis (UC) candidate Zeposia (ozanimod) at Digestive Disease Week (DDW), highlighting the drug's clinical benefits and safety profile.  According to one study, induction therapy with Zeposia improved symptoms of rectal bleeding and stool frequency in moderately to severely active UC patients as early as week two and maintained through week 10.

Bristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate Zeposia

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) in combination with Yervoy (ipilimumab), a subset of metastatic colorectal cancer (mCRC). The recommendation covers the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mCRC after prior fluoropyrimidine-based combination chemotherapy.

News for Bristol-Myers Stock (BMY)